Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD7503 in Healthy Japanese Participants
NCT06093542Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Primary completion
- Mar 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing AZD7503 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events. Started Oct 2023; status: completed.
02
Drugs
AZD7503
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06093542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093542.